Source: International Business Times
Under the deal, Novo gets the right to use PharmaShell in as many as five development programs for peptide-based medicines targeting obesity, type 2 diabetes and other cardiometabolic diseases. Sergei Gapon/AFP via Getty Images Shares of Swedish drug-delivery company Nanexa exploded higher Friday after the small biotech landed a licensing agreement worth as much as $1. 33 billion with Novo Nordisk, the pharmaceutical heavyweight behind blockbuster obesity drugs Wegovy and Ozempic.
Aller á la Source
Nouvelles connexes
